FDA Aligns on Interim Analysis for Phase 3 Pain Trial
The protocol update allows for a potential early conclusion for the trial investigating a treatment for CRPS-1.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Should regulatory bodies accelerate clinical trial milestones to bring new treatments to patients more quickly?
Ambros Therapeutics has reached alignment with the FDA to include an interim analysis in its Phase 3 CRPS-RISE trial for neridronate. This protocol update allows for a potential early clinical decision on the treatment of complex regional pain syndrome type 1.
Why it matters
The trial seeks to address a significant therapeutic gap, as there are currently no FDA-approved medications for the 65,000 patients diagnosed with CRPS-1 in the United States annually. Neridronate, which is already marketed in Italy, aims to be the first approved treatment for this condition in the U.S. market.
The CRPS-RISE study randomizes 270 participants to receive either a placebo or 400 mg of neridronate via four intravenous infusions. Efficacy is measured by pain intensity changes on an 11-point scale 12 weeks after treatment initiation.
The players
Ambros Therapeutics
A San Diego-based biopharmaceutical firm focused on developing neridronate for complex regional pain syndrome.
FDA
The United States federal agency responsible for regulating pharmaceuticals and ensuring drug safety and efficacy.
The details
Neridronate is a bisphosphonate, a class of drugs that inhibit bone resorption by interacting with osteoclasts, which are cells responsible for breaking down bone tissue. The CRPS-RISE trial evaluates its performance in patients with CRPS-1, a chronic pain condition characterized by inflammation and localized pain. The newly approved interim analysis will be managed by an independent data monitoring committee—an external panel of experts tasked with reviewing trial data to ensure participant safety and study integrity—once half of the enrolled participants have completed the study.
Timeline
Oct 26, 2026: Ambros Therapeutics announced FDA alignment on trial interim analysis.
Week 12: Primary efficacy endpoint measurement following treatment completion.
The Tech Race
Neridronate holds Orphan Drug and Fast Track designations from the FDA, positioning it as a frontrunner in the absence of any currently approved CRPS-1 therapies. This trial design modification follows established pathways to expedite evidence generation for conditions with high unmet medical needs.
The potential approval of neridronate could offer the first FDA-sanctioned pharmacological intervention for patients currently managing chronic CRPS-1 pain. Availability remains subject to the success of the ongoing CRPS-RISE clinical trial.
The takeaway
The interim analysis provides a critical mechanism for potentially shortening the time required to reach a definitive clinical outcome. Interested parties should watch for future updates regarding the revised statistical analysis plan and the committee charter submission.
Further reading
For broader trends in drug development and clinical validation, visit Biotech.
More information
Review the full clinicaltrials.gov trial record for complete study details.
Source note: This article includes information reported by The Manila times.
Live Poll
Should regulatory bodies accelerate clinical trial milestones to bring new treatments to patients more quickly?
